However, they observed shorter DFS and OS with increasing BMI category among women in the docetaxel cohort. For women with overweight vs. lean women, results showed adjusted HRs of 1.12 (95% CI ...

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

Contrast-enhanced chest, abdomen, and pelvic computed tomography or magnetic resonance imaging and bone scans were conducted at baseline, within 30 days of the last docetaxel cycle, and yearly during ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

During the study period, 79 CRPC patients received docetaxel-based chemotherapy at ... died of another cause. The median OS was 22.5 months, and the 1-year OS rate was 78.8 %.

The higher median PFS and OS observed with docetaxel was unexpected," said Dr. Besse. He noted that tusamitamab ravtansine showed better safety data in various important clinical categories.

Results showed a statistically significant improvement in OS with darolutamide plus docetaxel compared with placebo plus docetaxel (hazard ratio [HR], 0.68; 95% CI, 0.57-0.80; P <.0001).

In that time, studies of drugs involving Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq and Merck & Co.’s Keytruda have all failed to better the OS achieved by docetaxel. Gilead Sciences ...

Astellas and Pfizer have reported five-year follow-up outcomes from the open-label extension of the randomised Phase III ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX ... progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) when compared with FOLFOX ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...